Tyra Biosciences (TYRA) Operating Income (2020 - 2026)
Tyra Biosciences' (TYRA) quarterly Operating Income came in at -$42.0 million in Q1 2026, down 31.86% YoY from -$61.6 million in Q1 2025, and down 15.01% on a QoQ basis from -$36.5 million in Q4 2025.
Tyra Biosciences (TYRA) Operating Income (2020 - 2026) Analysis & Trends
Tyra Biosciences (TYRA) has 7 years of Operating Income data on file, last reported at -$42.0 million in Q1 2026.
- Quarterly Operating Income fell 31.86% year-over-year to -$42.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$142.9 million (down 25.66% YoY) and the FY2025 annual result came in at -$132.8 million, down 27.44% from the prior year.
- Operating Income declined to -$42.0 million in Q1 2026, from -$36.5 million in the prior quarter.
- In the past five years, Operating Income ranged from a high of -$13.6 million in Q3 2022 to a low of -$42.0 million in Q1 2026.
- A 5-year average of -$24.6 million and a median of -$24.0 million in 2023 frame the typical range for Operating Income.
- Annual changes were most pronounced in 2022 — Operating Income plunged 252.27% — and 2023, when it increased 3.37%.
- Tracing TYRA's Operating Income over 5 years: stood at -$15.0 million in 2022, then plunged by 70.69% to -$25.6 million in 2023, then decreased by 16.03% to -$29.7 million in 2024, then declined by 22.77% to -$36.5 million in 2025, then slipped by 15.01% to -$42.0 million in 2026.
- The last three Operating Income figures came in at -$42.0 million (Q1 2026), -$36.5 million (Q4 2025), and -$32.9 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Op. Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.29 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 493.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -505.13 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 325.05 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -3,158.03 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 133.12 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 231.44 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -1.55 Mn |
| 10 | Tyra Biosciences | 1.51 Bn | 1.51 Bn | - | -49.00 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -49.00 Mn |
| Mar 31, 2026 | -42.00 Mn |
| Dec 31, 2025 | -36.52 Mn |
| Sep 30, 2025 | -32.94 Mn |
| Jun 30, 2025 | -31.45 Mn |
| Mar 31, 2025 | -31.85 Mn |
| Dec 31, 2024 | -29.74 Mn |
| Sep 30, 2024 | -28.60 Mn |
| Jun 30, 2024 | -23.53 Mn |
| Mar 31, 2024 | -22.32 Mn |
| Dec 31, 2023 | -25.63 Mn |
| Sep 30, 2023 | -23.96 Mn |
| Jun 30, 2023 | -16.01 Mn |
| Mar 31, 2023 | -14.33 Mn |
| Dec 31, 2022 | -15.02 Mn |
| Sep 30, 2022 | -13.65 Mn |
| Jun 30, 2022 | -15.43 Mn |
| Mar 31, 2022 | -14.83 Mn |
| Dec 31, 2021 | -9.93 Mn |
| Sep 30, 2021 | -6.64 Mn |